This is a preview of subscription content, log in via an institution to check access.
Notes
Sponsorship for this study was funded by AstraZeneca Pharmaceuticals.
Reference
McEwan P, et al. Assessing the economic value of maintained improvements in Type 1 diabetes management, in terms of HbA1c, weight and hypoglycaemic event incidence. Diabetic Medicine : 27 Jan 2018. Available from: URL: http://doi.org/10.1111/dme.13590
Rights and permissions
About this article
Cite this article
The economic value of improved T1DM management. PharmacoEcon Outcomes News 796, 27 (2018). https://doi.org/10.1007/s40274-018-4701-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-4701-0